2024-11-15 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis

**1. Performance Comparison:**

Merck & Co Inc (MRK) is a pharmaceutical company that develops, manufactures, and markets a wide range of prescription medications, vaccines, and animal health products.

* **Cumulative return for MRK:** 93.88%
* **Cumulative return for S&P 500 (VOO):** 179.47%
* **Performance difference:** -85.59%
* **Relative performance:** 1.67 (meaning it's currently at the 1.67th percentile of its historical performance range compared to the S&P 500).

**Alpha and Beta Analysis:**
MRK has consistently shown positive CAGR and MDD, indicating strong growth potential and risk management. However, its Alpha values have been declining, suggesting its performance is becoming more aligned with the overall market. Its Beta values, on the other hand, are relatively stable, implying consistent market exposure. 

**2. Recent Price Movements:**

* **Closing price:** 98.5 (Last market: 98.97)
* **5-day moving average:** 100.38
* **20-day moving average:** 103.54
* **60-day moving average:** 110.64

MRK's price is currently below all three moving averages, indicating a downward trend in the short to medium term. 

**3. Technical Indicators:**

* **RSI:** 24.48 (below 30, indicating oversold conditions)
* **PPO:** -0.21 (negative value, confirming downward momentum)
* **Delta_Previous_Relative_Divergence:** -23.14 (indicating a recent 20-day relative price drop)
* **Expected Return:** 0.0% (indicating potential long-term outperformance relative to the S&P 500, despite recent price weakness).

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2024-11-06 | 1.87 | 15.96 B$ |

The latest earnings report (2024-11-06) showed a decline in EPS compared to previous quarters, potentially contributing to the recent downward price trend. However, the revenue figure remains relatively stable, demonstrating sustained demand for MRK's products. The analyst consensus for the next quarter is not yet available, but the current price reflects potential short-term volatility.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |

MRK's revenue has consistently remained above $15 billion, and profit margins have also been consistently high. This signifies a strong and stable financial performance.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50% |

Equity is gradually increasing, indicating sound financial management. ROE fluctuates, but remains generally positive, signaling the company's ability to generate profits from shareholders' investments.

**6. News and Recent Issues:**

* **Recent Earnings Announcement:** No recent news updates were found on Shacknews or other relevant sources regarding recent earnings announcements or any significant news impacting the company's performance.
* **Recent Market Outlook:** FINBOLD analysis suggests MRK is currently **undervalued** and presents an opportunity for long-term investors. The company is expected to benefit from strong product pipeline and continuous innovation. However, investors should also consider the potential impact of regulatory changes and increased competition in the pharmaceutical industry.
* **Analyst Opinions:** Analyst opinions on MRK are generally positive, with most analysts rating it as a **buy** or **hold**. Their target prices range from $110 to $125, indicating potential upside for the stock.

**7. Summary:**

MRK is a financially strong pharmaceutical giant with a history of stable growth and consistent profitability. However, its recent stock performance has lagged behind the S&P 500, and its latest earnings report shows a decline in EPS. Nevertheless, the company's strong revenue and solid financial position, coupled with the potential for long-term outperformance and positive analyst opinions, suggest it could be a worthwhile addition to a diversified portfolio for long-term investors.

**8. Recommendations:**

Given the current price and recent performance, it is recommended to **consider a long-term investment in MRK**, focusing on the company's potential for growth and future earnings prospects.  However, investors should closely monitor its upcoming earnings reports, the impact of regulatory changes on the pharmaceutical industry, and its ongoing competitive landscape.


**Disclaimer:** This information is for informational purposes only and is not intended as financial advice. 
